Series B · Biotech · Vienna, Austria · Founded 2018 · 51–200 employees
Ribbon Biolabs is a synthetic biology company that has developed a cell-free technology platform for the automated synthesis of long and complex DNA molecules. By leveraging its proprietary MiroSynth and InfiniSynth platforms, the company bypasses the length and sequence limits of traditional bacterial-mediated cloning. This approach allows biopharmaceutical researchers to bypass impurities and long turnaround times to access high-purity genetic constructs. The company expanded its market footprint by securing a Series B funding round of 5.17 million USD in February 2025.
No open roles listed right now.